TY - JOUR
T1 - Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma
AU - Kikuchi, Misato
AU - Nakasone, Hideki
AU - Akahoshi, Yu
AU - Nakano, Hirofumi
AU - Ugai, Tomotaka
AU - Wada, Hidenori
AU - Yamasaki, Ryoko
AU - Sakamoto, Kana
AU - Kawamura, Koji
AU - Ishihara, Yuko
AU - Sato, Miki
AU - Ashizawa, Masahiro
AU - Terasako-Saito, Kiriko
AU - Kimura, Shun Ichi
AU - Yamazaki, Rie
AU - Kako, Shinichi
AU - Kanda, Junya
AU - Nishida, Junji
AU - Sekiguchi, Naohiro
AU - Noto, Satoshi
AU - Kida, Michiko
AU - Hangaishi, Akira
AU - Usuki, Kensuke
AU - Kanda, Yoshinobu
N1 - Publisher Copyright:
© 2015 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia
PY - 2015
Y1 - 2015
N2 - Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.
AB - Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.
KW - Diffuse large B-cell lymphoma
KW - Elderly patients
KW - Neutropenia
KW - Non-Hodgkin lymphoma
KW - R-CHOP
KW - Relative dose intensity
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84923514218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923514218&partnerID=8YFLogxK
U2 - 10.1179/1973947814Y.0000000219
DO - 10.1179/1973947814Y.0000000219
M3 - Article
C2 - 25314911
AN - SCOPUS:84923514218
SN - 1120-009X
VL - 27
SP - 99
EP - 105
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - 2
ER -
